The effectiveness of selective percutaneous myofascial lengthening (SPML) and functional physiotherapy on gross motor function in children with cerebral palsy, aged 5-7 years

Not Applicable

Completed

• Conditions: cerebral palsy; spasticity; secondary musculotendinous contractures; Neurological - Other neurological disorders; Musculoskeletal - Other muscular and skeletal disorders

• Registration Number: ACTRN12618001535268
• Lead Sponsor: Vasileios Skoutelis

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2018-09-13
• Study Completion: 2020-03-05
• Last Update Posted: 12 April 2021

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 52

Inclusion Criteria

Spastic cerebral palsy,
Gross Motor Function Classification System (GMFCS) levels II-IV,
Normal or good cognitive ability,
Hip extensor strength higher than grade 2 via manual muscle testing.

Exclusion Criteria

Diagnosis other than cerebral palsy, dystonic or mixed motor disorder
Age outside the range
Gross Motor Function Classification System (GMFCS) levels I and V,
Severe cognitive disorders
Botulinum toxin injections within six months before the intervention
Previous orthopaedic procedures
Need for concomitant osteotomy
Hip flexor contracture
Hip extensor strength below manual muscle testing grade 3

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
D (Standing) dimension of the gross motor function measure (GMFM)[Baseline and 9 months after intervention commencement];Gross Motor Function Classification System (GMFCS) level [Baseline and 9 months after intervention commencement];Functional Mobility Scale (FMS)[Baseline and 9 months after intervention commencement]